International Myeloma Society Annual Meeting | Conference

Daratumumab Plus VRd Improves MRD Negativity in Newly Diagnosed, Transplant-Ineligible or -Deferred Myeloma

September 27th 2024

Daratumumab plus VRd improved MRD-negativity rates in transplant-ineligible or -deferred, newly diagnosed multiple myeloma.

Daratumumab/Lenalidomide Improves MRD– Conversion Rates in Newly Diagnosed Myeloma After ASCT

September 27th 2024

Daratumumab/lenalidomide maintenance increased MRD-negative conversion rates vs lenalidomide alone in newly diagnosed multiple myeloma after transplant.

Isa-KRd Induction Therapy Elicits Responses, MRD Negativity in Transplant-Eligible, Newly Diagnosed Myeloma

September 27th 2024

Patients with newly diagnosed, transplant-eligible multiple myeloma achieved deep responses and MRD negativity with isa-KRd induction therapy.

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

September 27th 2024

Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.

Talquetamab Plus Teclistamab Demonstrates Durable Responses in Triple Class–Exposed R/R Myeloma

September 27th 2024

Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.

D-VRd Extends PFS in Newly Diagnosed Multiple Myeloma Subgroups

September 26th 2024

D-VRd induction and consolidation therapy displayed a PFS benefit vs VRd in high-risk subgroups of patients with newly diagnosed multiple myeloma.

Belantamab Mafodotin Plus VRd Demonstrates Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma

September 26th 2024

Belantamab mafodotin-based combination appears to improve responses over time in those with transplant-eligible newly diagnosed multiple myeloma

Dr Liu on Epigenetic Regulation of CD38/CD48 in Multiple Myeloma

September 30th 2023

Jiye Liu, PhD, discusses epigenetic regulation of CD38/CD48 in multiple myeloma.

Dr Rasche on BCMA and GPRC5D Loss After Bispecific Antibody Therapy in Multiple Myeloma

September 30th 2023

Leo Rasche, MD, discusses BCMA and GPRC5D loss after bispecific antibody therapy in multiple myeloma.

Venetoclax/Carfilzomib/Dexamethasone Triplet Shows Early Efficacy in t(11;14)+ R/R Myeloma

September 30th 2023

The addition of venetoclax to carfilzomib and dexamethasone increased response rates compared with carfilzomib plus dexamethasone alone in patients with t(11:14)-positive relapsed/refractory multiple myeloma.

NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL Amyloidosis

September 30th 2023

The novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30th 2023

Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.

CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance in Multiple Myeloma

September 29th 2023

The EZH2 inhibitor tazemetostat may mimic the role of the KDM6A gene in upregulating CD38 and CD48 expression, suggesting that this agent could restore responses to daratumamab in patients with multiple myeloma, according to a presentation at the 20th International Myeloma Society Annual Meeting.

IberVd Elicits Durable Responses in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

September 29th 2023

The combination of iberdomide plus bortezomib and dexamethasone produced deep responses with a manageable toxicity profile in patients with transplant-ineligible, newly diagnosed multiple myeloma, according to data from the phase 1/2 CC-220-MM-001 trial presented at the 2023 International Myeloma Society Annual Meeting.

Teclistamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-Directed Therapy

September 29th 2023

Treatment with teclistamab led to responses in patients with relapsed/refractory multiple myeloma, including those previously exposed to anti-BCMA therapies.

Forimtamig Delivers Responses in Relapsed/Refractory Multiple Myeloma

September 29th 2023

Forimtamig monotherapy generated high overall response rates and durable responses in all subgroups of patients with relapsed/refractory multiple myeloma enrolled in a phase 1a dose-escalation trial.

Daratumumab-Based Quadruplets Show Consistent Efficacy in Newly Diagnosed Myeloma, Despite Early Relapse in Select Subsets

September 29th 2023

Although quadruplet combination regimens featuring daratumumab demonstrated consistent efficacy in the treatment of patients with newly diagnosed multiple myeloma, certain prognostic factors were associated with early relapse, according to data from a retrospective analysis presented at the 2023 International Myeloma Society Annual Meeting.

Teclistamab Delivers Comparable Efficacy Between Real-World and MajesTEC-1 Myeloma Populations

September 29th 2023

Treatment with teclistamab-cqyv in real-world patients with relapsed/refractory multiple myeloma elicited similar efficacy results and a comparable safety profile to findings from the phase 1/2 Majes-TEC-1 trial.

Daratumumab Plus KRd With Tandem Transplant Sustains Efficacy in High-Risk, Newly Diagnosed Myeloma

September 29th 2023

Induction daratumumab, carfilzomib, lenalidomide, and dexamethasone followed by consolidation double transplant sustained efficacy and safety in patients with high-risk, newly diagnosed multiple myeloma.

Dr Richter on the Optimal Dosing Schedule of Linvoseltamab in Multiple Myeloma

September 29th 2023

Joshua Richter, MD, discusses findings from the phase 1/2 LINKER-MM1 trial (NCT03761108) in multiple myeloma.